

1 P E
APR 16 2004
JC24
U.S. PATENT AND TRADEMARK OFFICE

Sheet 1 of 1

FORM PTO-2449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 480140.444C1	APPLICATION NO. 09/912,674
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Donal S. Karanewsky et al.	
		FILING DATE July 20, 2001	GROUP ART UNIT 1646 1654

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>DL</i>	AA	5,585,357	12/17/96	Dolle et al.	514	18	
	AB						
	AC						
	AD						
	AE						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
					YES NO
	AF				
	AG				
	AH				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>DL</i>	AI	Brennan, F.M et al., "Detection of transforming growth factor-beta in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures," <i>Clinical and Experimental Immunology</i> 81: 278-285, 1990.
<i>DL</i>	AJ	Frost, R.A. et al., "Lipopolysaccharide regulates proinflammatory cytokine expression in mouse myoblasts and skeletal muscle," <i>Am. J. Physiol. Regul. Interg. Comp. Physiol.</i> 283: R698-R709, September 2002.
<i>DL</i>	AK	Meyers, K.P. et al., "Effect of Treatment with Interleukin-1 Receptor Antagonist on the Development of Carrageenan-Induced Pleurisy in the Rat," <i>Inflammation</i> 17(2): 121-134, April 1993.
<i>DL</i>	AL	París, M.M. et al., "Effect of Interleukin-1 Receptor Antagonist and Soluble Tumor Necrosis Factor Receptor in Animal Models of Infection," <i>The Journal of Infectious Diseases</i> 171(1): 161-169, January 1995.
<i>DL</i>	AM	Read, S.J. et al., "Limiting Neurological Damage After Stroke. A Review of Pharmacological Treatment Options," <i>Drugs & Aging</i> 14(1): 11-39, January 1999.
<i>DL</i>	AN	Rosenbaum and Boney, "Activity of an Interleukin 1 Receptor Antagonist in Rabiit Models of Uveitis," <i>Archives of Ophthalmology</i> 110: 547-549, April 1992.

EXAMINER	<i>David L. Jackson</i>	DATE CONSIDERED
----------	-------------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 480140.444C1	APPLICATION NO. 09/912,674
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Donald S. Karanewsky et al.	
DEC 10 2001				FILING DATE July 20, 2001	GROUP ART UNIT 1646-1654

RECEIVED

PATENT TRADEMARK
OFFICE
U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

DEC 10 2001

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DL	AA 5,656,627	08/12/97	Bemis et al.	514	221	
DL	AB 5,714,484	02/03/98	Zimmerman et al.	514	231.5	
DL	AC 5,919,790	07/06/99	Allen et al.	514	278	
DL	AD 6,242,422 B1	06/05/01	Karanewsky et al.	514	19	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
DL	AE EP 623 592 B1	06/27/01	EPO		
	AF EP 623 606 B1	01/07/98	EPO		
	AG EP 644 197 B1	09/09/98	EPO		
	AH EP 761 680 A2	03/12/97	EPO		
	AI GB 2,292,149	02/14/96	UK		
	AJ WO 93/09135	05/13/93	WIPO		
	AK WO 95/05192	02/23/95	WIPO		
	AL WO 96/30395	10/03/96	WIPO		
	AM WO 97/22618	06/26/97	WIPO		
DL	AN WO 99/47545	09/23/99	WIPO		
DL	AO WO 99/66945	12/29/99	WIPO		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DL	AP	Dolle et al., "Pyridazinodiazepines as a High-Affinity, P2-P3 Peptidomimetic Class of Interleukin-1 β -Converting Enzyme Inhibitor," <i>J. Medicinal Chemistry</i> 40(13):1941-1945, June 20, 1997.
DL	AQ	Semple et al., "Peptidomimetic Aminomethylene Ketone Inhibitors of Interleukin-1 β -Converting Enzyme (ICE)," <i>Bioorganic & Medicinal Chemistry Letters</i> 8(8):959-964, April 21, 1998.

EXAMINER	David Lukan	DATE CONSIDERED
----------	-------------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).